Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial to studying the side effects of vaccine therapy in treating patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Study summary:

OBJECTIVES: - Determine the safety of NY-ESO-1b peptide vaccine and Montanide ISA-51 in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer expressing NY-ESO-1 or LAGE-1. - Determine the immunologic profile (NY-ESO-1 antibody, CD8+ cells, and delayed-type hypersensitivity) induced by this regimen in these patients. OUTLINE: This is an open-label study. Patients receive NY-ESO-1b peptide vaccine emulsified with Montanide ISA-51 subcutaneously once every 3 weeks on weeks 1, 4, 7, 10, and 13 in the absence of disease progression or unacceptable toxicity. Patients are followed at 3 weeks and then every 6-12 weeks for 2 years or until disease progression. PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer - Stage II-IV at diagnosis - Previously treated with cytoreductive surgery and at least 1 platinum-based chemotherapy regimen - High-risk feature, defined as 1 of the following: - Suboptimal primary debulking (remaining tumor masses with diameter at least 1.0 cm) - Failure to normalize CA 125 during primary therapy by the end of the third course - Complete clinical remission, defined as all of the following: - CA 125 less than 35 units - Negative physical examination - No definite evidence of disease by CT scan of the abdomen and pelvis* NOTE: *Lymph nodes and/or soft tissue abnormalities in the pelvis, no greater than 1.0 cm, are not considered definite evidence of disease - HLA-A2 positive - Tumor expression of 1 of the following proteins: - NY-ESO-1 by reverse transcriptase and polymerase chain reaction (RT-PCR) analysis or immunohistochemistry - LAGE-1 by RT-PCR - No more than 4 months since prior primary therapy - No CNS metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - Karnofsky 60-100% Life expectancy - At least 6 months Hematopoietic - Absolute neutrophil count at least 1,000/mm^3 - Platelet count at least 80,000/mm^3 - No bleeding disorders Hepatic - Bilirubin less than 2.5 times upper limit of normal (ULN) - ALT and AST less than 2.5 times ULN Renal - Creatinine no greater than 1.5 mg/dL Cardiovascular - No New York Heart Association class III or IV heart disease Other - Not pregnant or nursing - Fertile patients must use effective contraception - HIV negative - No serious infections requiring antibiotics - No serious concurrent illness requiring hospitalization - No other malignancy within the past 3 years except treated nonmelanoma skin cancer or carcinoma in situ of the cervix - No mental impairment that would preclude giving informed consent or complying with study requirements PRIOR CONCURRENT THERAPY: Biologic therapy - Not specified Chemotherapy - See Disease Characteristics - No concurrent chemotherapy Endocrine therapy - Concurrent tamoxifen is allowed - No concurrent systemic corticosteroids Radiotherapy - Not specified Surgery - See Disease Characteristics Other - More than 4 weeks since prior participation in any other investigational study - Concurrent non-cytotoxic anticancer therapy allowed - No concurrent immunosuppressive drugs - No concurrent nonsteroidal anti-inflammatory drugs except as low dose for the prevention of acute cardiovascular events or for pain control



Primary Contact:

Study Chair
Jakob Dupont, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.